NEWS

News Articles

FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

July 30, 2021

Availability of Insulin Products Will Help Increase Access and Potentially Lower the Cost of Insulin for People with Diabetes Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes…

Read More

Cell Constructs Rebrands to ProgenaCare Global In Commitment To Multi-Discipline Approach To Solve Problems of Wound Care Worldwide

July 30, 2021

Chronic wounds are a ubiquitous cause of suffering for humanity worldwide. Despite payors spending vast sums for treatment, suffering continues largely unabated. As part of its concerted effort to bring accessible solutions to this critical issue, Cell Constructs is changing its name to ProgenaCare Global to reflect its pioneering of a brand-new approach. The company…

Read More

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

July 30, 2021

Dive Brief: Amgen has agreed to acquire privately held biotech Teneobio for as much as $2.5 billion in a deal meant to broaden the big biotech’s ability to develop antibody drugs for cancer and potentially other diseases.   Per deal terms, Amgen will pay $900 million in cash for Teneobio and could add another $1.6 billion in downstream…

Read More

MiRus™ Raises $65 Million For Expansion of Rhenium-based Medical Devices

July 30, 2021

ATLANTA, July 27, 2021 /PRNewswire/ — MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®).  The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from…

Read More

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

July 22, 2021

PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad range of chronic and rare conditions, as well as urgent new health challenges like COVID-19. From new data released today, in 2020 alone, PhRMA member…

Read More

BD Seeks to Transform Patient Experience through Vision of ‘One-Stick Hospital Stay’

July 22, 2021

Acquisition of Velano Vascular Adds Innovative Needle-Free Blood Draw Technology to Reduce Pain and Discomfort of Multiple Needlesticks FRANKLIN LAKES, N.J., July 20, 2021 /PRNewswire/ –BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has taken a large step forward in transforming the patient experience through a vision of a “One-Stick…

Read More